Napolitano Maddalena, Fabbrocini Gabriella, Cinelli Eleonora, Stingeni Luca, Patruno Cataldo
Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy.
Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
J Asthma Allergy. 2020 Jan 31;13:89-94. doi: 10.2147/JAA.S206387. eCollection 2020.
Atopic dermatitis (AD) is the most common chronic cutaneous inflammatory disease of childhood, affecting up to 25% of children; its prevalence in adulthood is currently unknown, since studies reported that AD may affect 0.3-14.3% of adult population. In the last decade, the advanced understanding of AD molecular pathways along with patient's and physician's demand for more effective therapies, led to the introduction of new therapeutic agents. Baricitinib is an oral JAK inhibitor highly selective for JAK1 and JAK2. Treatment with baricitinib improved the signs and symptoms of moderate-to-severe AD compared to placebo, but it will be essential to better understand the safety profile of this drug.
特应性皮炎（AD）是儿童期最常见的慢性皮肤炎症性疾病，影响高达25%的儿童；目前其在成人中的患病率尚不清楚，因为研究报告显示AD可能影响0.3%-14.3%的成年人口。在过去十年中，随着对AD分子途径的深入了解以及患者和医生对更有效治疗方法的需求，新型治疗药物应运而生。巴瑞替尼是一种对JAK1和JAK2具有高度选择性的口服JAK抑制剂。与安慰剂相比，使用巴瑞替尼治疗改善了中重度AD的体征和症状，但更好地了解这种药物的安全性至关重要。
